- Home
- MKTW vs MTVA Comparison
MKTW vs MTVA Comparison
Compare MKTW & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- MTVA
- Stock Information
- Founded
- MKTW 1999
- MTVA 2014
- Country
- MKTW United States
- MTVA United States
- Employees
- MKTW N/A
- MTVA N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- MTVA
- Sector
- MKTW Technology
- MTVA
- Exchange
- MKTW Nasdaq
- MTVA NYSE
- Market Cap
- MKTW 22.2M
- MTVA 18.9M
- IPO Year
- MKTW N/A
- MTVA N/A
- Fundamental
- Price
- MKTW $0.51
- MTVA $1.85
- Analyst Decision
- MKTW Hold
- MTVA
- Analyst Count
- MKTW 1
- MTVA 0
- Target Price
- MKTW $2.00
- MTVA N/A
- AVG Volume (30 Days)
- MKTW 276.3K
- MTVA 256.5K
- Earning Date
- MKTW 11-07-2024
- MTVA 11-07-2024
- Dividend Yield
- MKTW 7.85%
- MTVA N/A
- EPS Growth
- MKTW N/A
- MTVA N/A
- EPS
- MKTW 0.13
- MTVA N/A
- Revenue
- MKTW $423,378,000.00
- MTVA N/A
- Revenue This Year
- MKTW N/A
- MTVA N/A
- Revenue Next Year
- MKTW N/A
- MTVA N/A
- P/E Ratio
- MKTW $3.92
- MTVA N/A
- Revenue Growth
- MKTW N/A
- MTVA N/A
- 52 Week Low
- MKTW $0.47
- MTVA $1.55
- 52 Week High
- MKTW $3.17
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- MKTW 42.90
- MTVA N/A
- Support Level
- MKTW $0.50
- MTVA N/A
- Resistance Level
- MKTW $0.53
- MTVA N/A
- Average True Range (ATR)
- MKTW 0.04
- MTVA 0.00
- MACD
- MKTW 0.00
- MTVA 0.00
- Stochastic Oscillator
- MKTW 22.41
- MTVA 0.00
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.